Women who suffer greater menopause symptoms are more likely to experience memory and thinking problems as they age, research has suggested.Experts found that women who recalled a heavier burden of ...

Q4 2024 Earnings Call Transcript March 6, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

Scientists have uncovered how ammonia wreaks havoc on liver cells by damaging mitochondria, leading to a dangerous cycle of toxicity. This discovery provides new hope as an existing drug, YAQ-005, ...

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...

The European Medicines Agency and Belgium’s Federal Agency for Medicines and Health Products have approved a Phase 2 challenge study on EV25, an antiviral therapeutic from Eradivir. The approval ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

(NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) ...

Thus, with low price valuations by the investors, these stocks will continue to offer returns that surpass the returns from ...

Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.